Prolonged, Severe Intrathecal Baclofen Withdrawal Syndrome: A Case Report


      Hansen CR, Gooch JL, Such-Neibar T. Prolonged, severe intrathecal baclofen withdrawal syndrome: a case report.
      Intrathecal baclofen (ITB) withdrawal is a well-recognized complication when drug delivery is disrupted for any reason. ITB withdrawal varies widely in its severity and poses the very real possibility of death if not promptly managed. Cases of withdrawal lasting greater than 1 or 2 weeks, however, are sparse. We report the case of an 11-year-old girl with spastic quadriplegic cerebral palsy who developed an infected pump and subsequent meningitis, prompting the removal of her pump and catheter. She subsequently developed a severe, prolonged baclofen withdrawal syndrome marked by increased spasticity, agitation, hypertension, and tachycardia that lasted nearly 2 months, requiring intensive care and continuous intravenous sedation with benzodiazepines and opiates. Her pump was eventually replaced on hospital day 56 and within 24 hours her symptoms dramatically improved. She was eventually weaned off sedating medications and returned to baseline functional status. Typical management of baclofen withdrawal is reviewed. To date, the literature has not discussed the potential role for opiates in managing baclofen withdrawal, yet a growing body of literature is examining the interplay between opiates and γ-aminobutyric acid B pathways. A potential role for opiates in managing severe baclofen withdrawal is proposed.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Archives of Physical Medicine and Rehabilitation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Albright A.L.
        • Gilmartin R.
        • Swift D.
        • Krach L.E.
        • Ivanhoe C.B.
        • McLaughlin J.F.
        Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin.
        J Neurosurg. 2003; 98: 291-295
        • Coffey R.J.
        • Cahill D.
        • Steers W.
        • et al.
        Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study.
        J Neurosurg. 1993; 78: 226-232
        • Albright A.L.
        • Barron W.B.
        • Fasick M.P.
        • Polinko P.
        • Janosky J.
        Continuous intrathecal baclofen infusion for spasticity of cerebral origin.
        JAMA. 1993; 270: 2475-2477
        • Gerszten P.C.
        • Albright A.L.
        • Barry M.J.
        Effect on ambulation of continuous intrathecal baclofen infusion.
        Pediatr Neurosurg. 1997; 27: 40-44
        • Gooch J.L.
        • Oberg W.A.
        • Grams B.
        • Ward L.A.
        • Walker M.L.
        Care provider assessment of intrathecal baclofen in children.
        Dev Med Child Neurol. 2004; 46: 548-552
        • Gooch J.L.
        • Oberg W.A.
        • Grams B.
        • Ward L.A.
        • Walker M.L.
        Complications of intrathecal baclofen pumps in children.
        Pediatr Neurosurg. 2003; 39: 1-6
        • Alden T.D.
        • Lytle R.A.
        • Park T.S.
        • Noetzel M.J.
        • Ojemann J.G.
        Intrathecal baclofen withdrawal: a case report and review of the literature.
        Childs Nerv Syst. 2002; 18: 522-525
        • Coffey R.J.
        • Edgar T.S.
        • Francisco G.E.
        • et al.
        Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome.
        Arch Phys Med Rehabil. 2002; 83: 735-741
        • Douglas A.F.
        • Weiner H.L.
        • Schwartz D.R.
        Prolonged intrathecal baclofen withdrawal syndrome.
        J Neurosurg. 2005; 102: 1133-1136
        • Bloom F.E.
        Neurotransmission and the central nervous system.
        in: Brunton L.L. Lazo J.S. Parker K.L. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. McGraw-Hill, New York2006: 330
        • Bennaroch E.E.
        • Daube J.R.
        • Sandok B.A.
        • Reagan T.J.
        • Westmoreland B.F.
        Medical neurosciences: an approach to anatomy, pathology, and physiology by systems and levels.
        4th ed. Lippincott Williams & Wilkins, Philadelphia1999 (p 376, 406)
        • Kroin J.S.
        • Bianchi G.D.
        • Penn R.D.
        Intrathecal baclofen down-regulates GABAB receptors in the rat substantia gelatinosa.
        J Neurosurg. 1993; 79: 544-549
        • Meythaler J.M.
        • Roper J.F.
        • Brunner R.C.
        Cyproheptadine for intrathecal baclofen withdrawal.
        Arch Phys Med Rehabil. 2003; 84: 638-642
        • Khorasani A.
        • Peruzzi W.T.
        Dantrolene treatment for abrupt intrathecal baclofen withdrawal.
        Anesth Analg. 1995; 80: 1054-1056
        • Addolorato G.
        • Leggio L.
        • Agabio R.
        • Colombo G.
        • Gasbarrini G.
        Baclofen: a new drug for the treatment of alcohol dependence.
        Int J Clin Pract. 2006; 60: 1003-1008
        • Addolorato G.
        • Leggio L.
        • Abenavoli L.
        • et al.
        Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam.
        Am J Med. 2006; 119 (e13-8): 276
        • Sofuoglu M.
        • Kosten T.R.
        Novel approaches to the treatment of cocaine addiction.
        CNS Drugs. 2005; 19: 13-25
        • Assadi S.M.
        • Radgoodarzi R.
        • Ahmadi-Abhari S.A.
        Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial [ISRCTN32121581].
        BMC Psychiatry. 2003; 3: 16
        • Akhondzadeh S.
        • Ahmadi-Abhari S.A.
        • Assadi S.M.
        • Shabestari O.L.
        • Kashani A.R.
        • Farzanehgan Z.M.
        Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal.
        J Clin Pharm Ther. 2000; 25: 347-353
        • Leite-Morris K.A.
        • Fukudome E.Y.
        • Shoeb M.H.
        • Kaplan G.B.
        GABA(B) receptor activation in the ventral tegmental area inhibits the acquisition and expression of opiate-induced motor sensitization.
        J Pharmacol Exp Ther. 2004; 308: 667-678
        • Ford C.P.
        • Mark G.P.
        • Williams J.T.
        Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location.
        J Neurosci. 2006; 26: 2788-2797
        • Suzuki T.
        • Nurrochmad A.
        • Ozaki M.
        • et al.
        Effect of a selective GABA(B) receptor agonist baclofen on the mu-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects.
        Neuropharmacology. 2005; 49: 1121-1131
        • Kroin J.S.
        Intrathecal drug administration, present use and future trends.
        Clin Pharmacokinet. 1992; 22: 319-326
        • Soni B.M.
        • Mani R.M.
        • Oo T.
        Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance—a case report and review of the literature.
        Spinal Cord. 2003; 41: 586-589